logo
West Virginia bans 7 artificial food dyes, citing potentially harmful health effects

West Virginia bans 7 artificial food dyes, citing potentially harmful health effects

CBS News25-03-2025

West Virginia has outlawed foods that contain
some artificial dyes
or other additives, in one of the most comprehensive statewide bans of its kind. The move cites potentially harmful health effects and comes amid a broader push from scientists and government leaders to clamp down on synthetics in the nation's food supply.
On Monday, West Virginia Gov. Patrick Morrisey
signed
into law a bill that was passed earlier by legislators to eliminate seven artificial dyes — Red Dye No. 3, Red Dye No. 40, Yellow Dye No. 5, Yellow Dye No. 6, Blue Dye No. 1, Blue Dye No. 2 and Green Dye No. 3 — from food products and drugs sold in the state. The preservatives butylated hydroxyanisole and propylparaben will also be banned.
The dyes will not be allowed in meals served as part of school nutrition programs starting on Aug. 1 this year, while the dyes and the two preservatives will not be permitted in drugs and food sold in the state starting on Jan. 1, 2028, according to the governor's office.
"West Virginia ranks at the bottom of many public health metrics, which is why there's no better place to lead the Make America Healthy Again mission," Morrisey said in a statement, citing the campaign slogan popularized by Health and Human Services Secretary Robert F. Kennedy Jr., who has said he is prioritizing the removal of artificial dyes from food and drinks sold around the United States. "By eliminating harmful chemicals from our food, we're taking steps toward improving the health of our residents and protecting our children from significant long-term health and learning challenges."
The latest ban in West Virginia follows a pair of laws passed in California in recent years to remove some additives from foods sold statewide and
synthetic dyes from school meals
. Dozens of other U.S. states have introduced legislation to ban or more strictly regulate certain food additives, including artificial dyes, since the beginning of the year, according to the
Environmental Working Group
, an advocacy organization focused on food safety.
Thirty-six color additives are
approved by the Federal Drug Administration
for use in food and drinks in the U.S., including nine artificial dyes.
Rising concerns from advocacy groups and scientists about possible health consequences of synthetic food components, particularly for children, prompted the FDA to
undertake a new effort
in December to review previously approved additives, although the agency's deputy commissioner for human foods warned at the time that budget restrictions might prevent a timely turnaround. In January, the FDA announced its decision to
revoke the authorization
for one dye, Red 3, to be added to foods, after evidence showed a link between the dye and cancer in laboratory animals.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Cleveland health officials warn COVID spike is coming
Cleveland health officials warn COVID spike is coming

Yahoo

time2 hours ago

  • Yahoo

Cleveland health officials warn COVID spike is coming

[Watch in the player above: How to know whether you have COVID, flu, RSB or strep] CLEVELAND (WJW) — Cleveland Department of Public Health officials said a sharp uptick in COVID gene copies recently detected in city wastewater samples indicates a 'strong likelihood of increased community spread in the coming days or weeks.' Sampling last week of untreated wastewater from the Northeast Ohio Regional Sewer District's Easterly Wastewater Treatment Plant shows a more than 250% increase in the SARS-CoV-2 viral levels between June 8 and June 10, according to a Friday news release from the health department. Massive egg recall hits Ohio Walmart stores The sampling also showed high levels of influenza that are still 'trending upward' as well as high levels of respiratory syncytial virus, or RSV. SARS-CoV-2, the virus that causes COVID-19, can be shed through feces — even by people who aren't yet showing symptoms of infection — so wastewater sampling can help detect community spread early. 'Increasing viral concentrations in wastewater are often a leading indicator of future spikes in illness, hospitalizations and transmission throughout the community,' Cleveland Director of Public Health Dr. David Margoulis is quoted in the release. 'This data provides us with an early warning system, and we're encouraging residents and institutions to take preventive steps now.' The health department urges residents to get their shots or boosters for COVID-19 and the flu and urges people who are experiencing respiratory symptoms to stay home or wear a mask if they need to go out in public. Iran fires missiles at Israel in retaliation The World Health Organization is tracking a new COVID-19 variant called NB.1.8.1, or 'Nimbus' that is more transmissible than other variants, The Hill reported this week. Its symptoms appear to be similar to those caused by other COVID variants: cough, fever, fatigue, muscle aches and loss of smell or taste, according to the CDC. As of Wednesday, June 11, the Nimbus variant had been found in 13 states, including Ohio. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Cherokee Nation hosts second annual Rare Disease Summit
Cherokee Nation hosts second annual Rare Disease Summit

Yahoo

time2 hours ago

  • Yahoo

Cherokee Nation hosts second annual Rare Disease Summit

TAHLEQUAH, Okla. — Rare diseases affect an estimated 1 in 10 Americans and consist of over 7,000 known conditions. These staggering figures prompted the Cherokee Nation to host its second Rare Disease Summit this week. The summit brought together health care professionals, medical specialists, and the community to better address the unique challenges facing tribal citizens with rare medical conditions. 'Cherokee Nation has always been committed to meeting the health care needs of our citizens, no matter how complex or challenging those needs may be.' Principal Chief Chuck Hoskin Jr. According to the National Institute of Health, any disease affecting fewer than 200,000 people in the United States is rare, and more than 90 percent lack FDA-approved treatments. 'Our second annual Rare Disease Summit demonstrates our unwavering dedication to ensuring that no Cherokee citizen faces a rare disease diagnosis alone,' Hoskin said. 'By bringing together leading medical experts, patients, families, and advocates, we're building a stronger support network and advancing care options that can make a real difference in people's lives.' He said that this summit represents the Cherokee values of working together and leaving no one behind. This year's summit featured expert speakers across multiple medical specialties, including neurology, rheumatology, optometry, infectious disease, and pediatrics. Attendees participated in an interactive question-and-answer panel and explored a resource fair designed to provide comprehensive information and support. Summit attendees also had the opportunity to take part in various breakout sessions throughout the day that covered the following topics: the Newborn and Rare Disease Screening Program; building partnerships to optimize Cystic Fibrosis care in children and adults; genetic testing for epilepsies; mental health in the perinatal period; rare genetic variants and their role in diabetes and vascular diseases; Pediatric Neurovascular Disease; Ehlers Danlos Syndrome; and Spina Bifida and Chiari. Cherokee Nation's health care system, the largest tribally operated health system in Indian Country, is committed to finding solutions and increasing resources for people with rare disease conditions by raising awareness, advocating for policy change, and building a growing support network. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Rakuten Medical Selected to Participate in FDA CEO Forum in San Diego
Rakuten Medical Selected to Participate in FDA CEO Forum in San Diego

Yahoo

time2 hours ago

  • Yahoo

Rakuten Medical Selected to Participate in FDA CEO Forum in San Diego

- Engaged with FDA Commissioner on shared commitment to fast, safe, and affordable patient access to innovative therapies SAN DIEGO, June 13, 2025 /PRNewswire/ -- Rakuten Medical, Inc., a global biotechnology company developing and commercializing Alluminox™ platform-based photoimmunotherapy, today announced that it was selected by the U.S. Food and Drug Administration (FDA) to participate in the FDA CEO Forum in San Diego, California, on June 13, 2025. Minami Maeda, President of Rakuten Medical, attended the meeting in person as a member of this panel, to discuss with FDA Commissioner Marty A. Makary, M.D., M.P.H., and other industry leaders how the FDA can "modernize its regulatory framework to better support innovation and patient access to safe and effective therapies". Rakuten Medical – whose innovative cancer therapeutic technology, the Alluminox™ platform, is in Phase 3 trials in the U. S. – was selected to join the forum as one of the companies at the front lines of medical discovery. Rakuten Medical's novel treatment modality, known as photoimmunotherapy, is designed to induce rapid and selective depletion of cancer or immunosuppressive cells with minimal impact on surrounding healthy tissue. Moreover, pre-clinical observation have shown that photoimmunotherapy may also stimulate both innate and adaptive anti-tumor immune responses. "Rakuten Medical's Alluminox™ platform has the potential to transform cancer therapy in the U.S.," said Maeda. "We are honored to be recognized by the FDA and invited to contribute to discussions on how regulatory innovation can accelerate the delivery of pioneering treatments to patients. We fully support the FDA's vision of a modern framework that ensures timely access, safety, and affordability." Rakuten Medical is currently conducting a global Phase 3 clinical trial evaluating its ASP-1929 photoimmunotherapy in combination with pembrolizumab as a first-line treatment for patients with recurrent head and neck squamous cell carcinoma (HNSCC) (Protocol number: ASP-1929-381 / Acronym: ECLIPSE / Identifier: NCT06699212). A prior Phase 1b/2 study showed promising interim evaluation results, including a 24-month survival rate of 52.4% and a median overall survival (OS) not yet reached. ASP-1929 photoimmunotherapy received the world's first regulatory approval in Japan under the Conditional Early Approval System based on a certain level of efficacy and acceptable safety from Phase 1/2a trial results. It is being delivered to patients in Japan at an affordable price. Disclaimer: Rakuten Medical's Alluminox™ platform-based photoimmunotherapy is investigational outside Japan. About Rakuten Medical, Inc. Rakuten Medical, Inc. is a global biotechnology company developing and commercializing Alluminox™ platform-based photoimmunotherapy, which, in pre-clinical studies, has been shown to induce rapid and selective cell killing. Rakuten Medical's photoimmunotherapy is currently investigational outside Japan. Rakuten Medical is committed to its mission to conquer cancer by developing its pioneering treatments as quickly as possible to as many patients as possible all over the world. The company has offices in 5 countries/regions, including the United States, where it is headquartered, Japan, Taiwan, Switzerland and India. For more information, visit About Alluminox™ platform The Alluminox™ platform is Rakuten Medical's investigational technology platform that combines pharmaceuticals, medical devices, medical technology, and other peripheral technologies. Rakuten Medical is developing Alluminox platform-based photoimmunotherapy, which involves two key steps: 1) drug administration and 2) targeted illumination using medical devices. The drug component consists of a cell-targeting moiety conjugated to a light-activatable dye, such as IRDye® 700DX (IR700), that selectively binds to the surface of targeted cells, such as tumor cells. The device component consists of a light source that locally illuminates the targeted cells with red light (690nm) to transiently activate the drug. Rakuten Medical's pre-clinical data have shown that this activation elicits rapid and selective necrosis of targeted cells through a biophysical process that compromises the membrane integrity of the targeted cells. Therapies developed on the Alluminox platform may also result in local and systemic innate and adaptive immune activation due to immunogenic cell death of the targeted tumor cells and/or the removal of targeted immunosuppressive cells within the tumor microenvironment. Photoimmunotherapy was originally developed by Dr. Hisataka Kobayashi and his team at the National Cancer Institute in the United States. Outside Japan, Rakuten Medical's Alluminox platform-based photoimmunotherapy is investigational. About ASP-1929Rakuten Medical's first pipeline drug developed on its Alluminox™ platform is ASP-1929, an antibody-dye conjugate comprised of the anti-EGFR antibody cetuximab and IRDye® 700DX, a light activatable dye. ASP-1929 binds to epidermal growth factor receptor (EGFR), a cancer antigen expressed in multiple types of solid tumors, including head and neck, breast, lung, colorectal, prostate and pancreatic cancers. After binding to cancer cells, ASP-1929 is locally activated by illumination with red light (690 nm), emitted by a laser device system to produce a photochemical reaction. This reaction is believed to cause damage to the membrane of cancer cells, leading to selective necrosis of cancer cells. In Japan, ASP-1929 received marketing approval from the Japanese Ministry of Health, Labor, and Welfare for unresectable locally advanced or recurrent head and neck cancer in September 2020, under the Sakigake Designation System and the Conditional Early Approval System. ASP-1929 photoimmunotherapy in combination with pembrolizumab is currently under investigation in a global Phase 3 clinical trial as a first-line therapy for recurrent head and neck cancer. Outside Japan, ASP-1929 has not yet been approved for commercial use by any regulatory authority. Contact Us View original content to download multimedia: SOURCE Rakuten Medical, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store